Skip to main content
Psych Congress  

The NeuroStar Outcomes Registry


Todd Hutton, MD – Southern California TMS Center; Miriam Mina, BS – Neuronetics, Inc.; Karen Heart, NA – Neuronetics, Inc.

Neuronetics, Inc.

NeuroStar® Advanced Therapy System is an effective acute treatment for patients with Major Depressive Disorder (MDD). To further understand the efficacy of the NeuroStar in a clinical setting, Neuronetics has established a patient treatment and Outcomes Registry to collect and analyze the efficacy of transcranial magnetic stimulation (TMS) on patients receiving NeuroStar treatment. An integrated electronic data management system (TrakStar) allows for the large-scale data collection to be automated. De-identified patient data is uploaded to a Registry server; an independent statistical service then creates final data reports. The data collected for the registry include Demographic Elements (age, gender), Treatment Parameters, and Clinical Ratings (PHQ-9 and CGI-S) at baseline and the end of acute treatment. The NeuroStar Outcomes Registry has demonstrated comparable results to that of a previous naturalistic observational study of TMS treatment outcomes (Carpenter et al., 2012). The NeuroStar Outcomes Registry is ongoing with over 3300 evaluable patients enrolled from more than 100 clinical sites in 3 years. Of these patients, approximately 2/3 patients achieve response and 1/3 of the patients achieve remission in an acute course of NeuroStar TMS treatment.

This poster was presented at the 32nd annual Psych Congress, held Oct. 3-6, 2019, in San Diego, California.

Back to Top